美国疾病控制与预防中心(CDC)最新发布的研究显示,2025年约有9.8%的美国成年人使用GLP-1受体激动剂,这一比例对应约2700万人 1。该研究数据发表于CDC《发病率与死亡率周报》,调查时间跨度为2025年7月至8月,样本覆盖超过8000名美国成年人 1。研究发现,在GLP-1药物的使用者中,有44%的人报告以不同于处方的方式使用药物,具体行为包括跳过剂量或延迟续药等 1。
导致这种非规范用药的主要驱动因素是经济负担和获取难度,超过一半修改用药方式的人表示原因是成本或可及性问题 1。不同年龄群体在这一问题上表现出显著差异:在14至39岁的年轻用户中,有58%将成本列为主要障碍,而在65岁以上的老年用户中,这一比例仅为20% 1。研究人员强调,这种普遍的用药行为偏离处方要求带来了潜在的安全隐患并可能影响治疗效果 1。
Recent data from the Centers for Disease Control and Prevention (CDC) indicates that nearly half of American adults using GLP-1 receptor agonists are not adhering to their prescribed medication regimens 1. The study, published in the CDC’s Morbidity and Mortality Weekly Report, reveals that 44% of respondents who used these drugs reported taking them differently than directed, including skipping doses or delaying refills 1. This finding comes from a survey conducted between July and August 2025, which covered more than 8,000 U.S. adults 1.
The primary driver behind this non-compliance is financial constraint and accessibility issues 1. More than half of those who altered their usage patterns cited cost or difficulty in obtaining the medication as the main reasons 1. A significant age disparity exists in how these barriers affect behavior: 58% of users aged 14 to 39 identified cost as an obstacle, compared to only 20% of those aged 65 and older 1. Overall, approximately 9.8% of U.S. adults, totaling around 27 million people, used GLP-1 medications in 2025 1.
评论
还没有评论,欢迎留下第一条。